VKORC1

Warfarin, a commonly used anti-clotting drug, sold under the brand name of Coumadin, has a been a poster child for the promise of pharmacogenomics and personalized medicine. The excitement has come from the idea that knowing a patient's genotype, in this case for the VKORC1 and CYP2C9 genes, would allow physicians to tailor the dose of the drug and get patients the correct dose more quickly. And it seems obvious that a test that would allow doctors to predict your ability to metabolize warfarin, would be a great thing, right? Figure 1. Human Cytochrome P450 Cyp2c9 bound to Warfarin…